Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seralutinib in Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07181382Phase 3Suspended
- Sponsor
- GB002, Inc.
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of seralutinib in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by GB002, Inc.. Started Feb 2026; status: suspended.
02
Drugs
seralutinib
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT07181382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181382.